Sen. Peter Welch (D-Vt.) endorsed President Trump's push to align U.S. drug prices with international markets on Wednesday, signaling Democratic willingness to move forward on a pharmaceutical cost-containment strategy that has emerged as rare common ground in Congress.
Speaking at the Axios Future of Health summit, Welch said he would not merely support Trump's most-favored nation framework but actively champion its passage into law. "I would not only vote for it, I would work actively and aggressively to make it happen," he told moderator Peter Sullivan.
The endorsement carries weight as lawmakers weigh how to respond to Trump's existing deals with at least 16 drug manufacturers. Those agreements aim to cap what Americans pay for prescriptions at levels closer to what patients in other developed nations face, though the specific terms remain confidential.
Welch's support comes with a caveat: he wants Trump to follow through legislatively. The senator pressed the president to introduce formal legislation rather than rely solely on executive agreements. "Do it, not just talk about it," Welch said.
The Vermont Democrat is already collaborating across the aisle on this front. He and Sen. Josh Hawley (R-Mo.) have crafted a bipartisan bill that would prohibit drugmakers from charging Americans more than the international average price. When Welch unveiled that proposal in May, he framed it as a Congressional template for the Trump administration to use.
Public concern about medication affordability provides political momentum. A majority of Americans express at least some worry about their ability to pay for prescription drugs, creating pressure on lawmakers to address the issue.
The secrecy surrounding Trump's pharmaceutical deals has drawn skepticism from some Democrats, who worry the arrangements might ultimately benefit industry more than patients. That criticism underscores why legislative codification matters. A formal bill would establish transparent rules and enforcement mechanisms that executive orders cannot provide.
With Welch's public backing, Trump now has concrete Democratic support for pursuing price alignment. Whether that translates into actual legislation depends on whether the administration chooses to pursue a legislative route and whether broader congressional coalition-building gains traction on Capitol Hill.
Author James Rodriguez: "Welch's willingness to work with Trump on drug pricing shows the issue has real bipartisan legs, but talk is cheap without the bills to prove it."
Comments